Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer

Outcomes for metastatic colorectal cancer (mCRC) patients have been improved by treatment with anti-epidermal growth factor receptor (anti-EGFR) antibodies, particularly when combined with predictive biomarkers to select patients lacking RAS mutations. New technologies such as liquid biopsy and next...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyamoto, Yuji, Suyama, Koichi, Baba, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412337/
https://www.ncbi.nlm.nih.gov/pubmed/28368335
http://dx.doi.org/10.3390/ijms18040752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412337/
https://www.ncbi.nlm.nih.gov/pubmed/28368335
http://dx.doi.org/10.3390/ijms18040752

Ejemplares similares